Leerink Partners has shifted its view on Johnson & Johnson, elevating the stock from "Market Perform" to "Outperform" and increasing its 12-month price objective to $265 from $252. The new target implies roughly 18% upside from the company’s recent closing price, according to the brokerage.
At the heart of Leerink’s more bullish stance is an expectation that J&J is entering a phase of accelerated revenue growth driven by a slate of launches and expanding oncology and immunology franchises. Leerink now models a compound annual revenue growth rate of 7.2% for Johnson & Johnson for the 2026-2031 period, versus what the brokerage described as Wall Street consensus expectations of about 6%.
The firm identified four core products it believes will underpin the stronger revenue trajectory:
- Icotyde - Described by Leerink as a potential blockbuster, Icotyde is an oral IL-23 therapy that launched in April 2026 for psoriasis. The brokerage highlighted its strong efficacy data and the advantage of oral dosing compared with injectable biologics. Leerink projects Icotyde could reach $10.5 billion in sales by 2032, materially above current consensus estimates cited by the firm.
- Inlexzo - Marketed via the TAR-200 delivery system for bladder cancer, Inlexzo was spotlighted for robust patient demand and improved reimbursement dynamics following a permanent U.S. J-code assignment in April. Leerink also noted expanded treatment recommendations from the National Comprehensive Cancer Network and forecasts Inlexzo could achieve $5.8 billion in annual sales by 2032.
- Rybrevant - The lung cancer therapy saw a regulatory development in December 2025 when a subcutaneous formulation was approved. Leerink said the new formulation meaningfully improved safety and convenience, which could accelerate uptake in first-line EGFR-mutated non-small cell lung cancer. The report recorded a 22% sequential increase in U.S. sales for Rybrevant in the first quarter of 2026.
- Tremfya - The psoriasis and inflammatory bowel disease treatment continues to register solid prescription growth, with Leerink citing strong uptake in inflammatory bowel disease indications as a contributor to ongoing momentum.
Leerink also flagged a pipeline calendar that could feed further positive sentiment: multiple late-stage data readouts expected in 2026, including outcomes for Icotyde, Inlexzo, and Johnson & Johnson’s multiple myeloma candidates Talvey and Tecvayli.
Despite the upgraded recommendation, the brokerage emphasized that risks remain. Those include clinical trial setbacks, the possibility of weaker-than-expected commercial launches, ongoing litigation exposure related to talc liabilities, and the challenges posed by broader drug pricing pressures.
Market implications - Leerink’s revision of J&J’s revenue outlook and price target reflects a market view that successful execution on new product launches and favorable reimbursement and guideline developments could meaningfully lift near- to medium-term top-line growth. The upgrade may influence investor sentiment for large-cap pharmaceutical and healthcare stocks more broadly.